

Cecile L Tremblay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4042920/publications.pdf>

Version: 2024-02-01

50
papers

2,300
citations

331670

21
h-index

233421

45
g-index

50
all docs

50
docs citations

50
times ranked

3715
citing authors

#	ARTICLE	IF	CITATIONS
1	Associative prediction of carotid artery plaques based on ultrasound strain imaging and cardiovascular risk factors in people living with HIV and age-matched control subjects of the CHACS cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2022, Publish Ahead of Print, .	2.1	0
2	Covid-19 vaccine immunogenicity in people living with HIV-1. <i>Vaccine</i> , 2022, 40, 3633-3637.	3.8	47
3	Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 664371.	4.8	25
4	Prevalence and Characterization of Subclinical Coronary Atherosclerotic Plaque with CT among Individuals with HIV: Results from the Canadian HIV and Aging Cohort Study. <i>Radiology</i> , 2021, 299, 571-580.	7.3	17
5	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T _H 1 cell responses. <i>Cell Host and Microbe</i> , 2021, 29, 1137-1150.e6.	11.0	173
6	Dynamics and epigenetic signature of regulatory T-cells following antiretroviral therapy initiation in acute HIV infection. <i>EBioMedicine</i> , 2021, 71, 103570.	6.1	12
7	Impact of cobas PCR Media freezing on SARS-CoV-2 viral RNA integrity and whole genome sequencing analyses. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115521.	1.8	2
8	Circulating (1 α) ²⁵ -D ₂ -glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2020, 70, 232-241.	5.8	66
9	Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls. <i>Clinical Infectious Diseases</i> , 2020, 71, 1438-1446.	5.8	40
10	Plasma Levels of C-Type Lectin REG3 β and Gut Damage in People With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2020, 221, 110-121.	4.0	43
11	Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa404.	0.9	3
12	Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV. <i>Medicine (United States)</i> , 2020, 99, e23335.	1.0	3
13	Increased carotid artery wall stiffness and plaque prevalence in HIV infected patients measured with ultrasound elastography. <i>European Radiology</i> , 2020, 30, 3178-3187.	4.5	20
14	A Short-Term Assessment of Nascent HIV-1 Transmission Clusters Among Newly Diagnosed Individuals Using Envelope Sequence-Based Phylogenetic Analyses. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 906-919.	1.1	0
15	Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals. <i>Viruses</i> , 2019, 11, 487.	3.3	10
16	CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection. <i>Frontiers in Immunology</i> , 2019, 10, 289.	4.8	57
17	HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses. <i>Viruses</i> , 2019, 11, 1012.	3.3	4
18	The anti-inflammatory IL-37/SIGIRR axis is functionally compromised in HIV infection. <i>Aids</i> , 2019, 33, 1693-1703.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 503-513.	2.1	21
20	HIV-1 capsids from B27/B57+ elite controllers escape Mx2 but are targeted by TRIM5 β , leading to the induction of an antiviral state. <i>PLoS Pathogens</i> , 2018, 14, e1007398.	4.7	25
21	Gonorrhea, Chlamydia and HIV incidence among female sex workers in Cotonou, Benin: A longitudinal study. <i>PLoS ONE</i> , 2018, 13, e0197251.	2.5	13
22	The Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis. <i>Viruses</i> , 2018, 10, 65.	3.3	51
23	Anti-Gag antibodies gag HIV infection and slow disease progression. <i>Aids</i> , 2018, 32, 1373-1375.	2.2	3
24	HIV induces production of IL-18 from intestinal epithelial cells that increases intestinal permeability and microbial translocation. <i>PLoS ONE</i> , 2018, 13, e0194185.	2.5	31
25	Differential synthesis and release of IL-18 and IL-18 Binding Protein from human platelets and their implications for HIV infection. <i>Cytokine</i> , 2017, 90, 144-154.	3.2	20
26	Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. <i>Cmaj</i> , 2017, 189, E1448-E1458.	2.0	149
27	A potentially protective role of IL-18 Binding Protein in HIV-infected Long-Term Non-Progressors. <i>Cytokine</i> , 2017, 90, 96-99.	3.2	2
28	HIV-1 envelope sequence-based diversity measures for identifying recent infections. <i>PLoS ONE</i> , 2017, 12, e0189999.	2.5	8
29	The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol. <i>BMC Infectious Diseases</i> , 2017, 17, 611.	2.9	45
30	Clinical and Molecular Epidemiology of <i>Histoplasma capsulatum</i> in Quebec, Canada. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
31	Coronary calcium assessment with computed tomography in HIV-infected patients. <i>Atherosclerosis</i> , 2016, 249, 99-100.	0.8	0
32	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. <i>EBioMedicine</i> , 2016, 12, 208-218.	6.1	65
33	Imbalanced production of IL-18 and its antagonist in human diseases, and its implications for HIV-1 infection. <i>Cytokine</i> , 2016, 82, 38-51.	3.2	31
34	Performance of Bio-Rad and Limiting Antigen Avidity Assays in Detecting Recent HIV Infections Using the Quebec Primary HIV-1 Infection Cohort. <i>PLoS ONE</i> , 2016, 11, e0156023.	2.5	13
35	Impaired Th17 polarization of phenotypically naive CD4+ T-cells during chronic HIV-1 infection and potential restoration with early ART. <i>Retrovirology</i> , 2015, 12, 38.	2.0	30
36	Identification of novel HIV-1 dependency factors in primary CCR4+CCR6+Th17 cells via a genome-wide transcriptional approach. <i>Retrovirology</i> , 2015, 12, 102.	2.0	54

#	ARTICLE	IF	CITATIONS
37	The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2015, 89, 545-551.	3.4	173
38	Synergistic Combinations of the CCR5 Inhibitor VCH-286 with Other Classes of HIV-1 Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7565-7569.	3.2	9
39	Performance of a clonal-based HIV-1 tropism phenotypic assay. <i>Journal of Virological Methods</i> , 2014, 204, 53-61.	2.1	5
40	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. <i>Journal of Virological Methods</i> , 2014, 208, 107-114.	2.1	62
41	Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance. <i>AIDS Research and Therapy</i> , 2013, 10, 15.	1.7	7
42	Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. <i>Vaccine</i> , 2011, 29, 1359-1363.	3.8	32
43	Association Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and Nested Case-Control Study Using Quebec's Public Health Insurance Database. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 245-253.	2.1	257
44	Challenges in Initiating Antiretroviral Therapy in 2010. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010, 21, 1C-15C.	1.9	1
45	Challenges in initiating antiretroviral therapy in 2010. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010, 21 Suppl C, 1C-15C.	1.9	0
46	Combating HIV resistance – focus on darunavir. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 759-765.	2.0	28
47	High Rates of Forward Transmission Events after Acute/Early HIV Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 951-959.	4.0	608
48	TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals <i>in Vitro</i> . <i>Antiviral Therapy</i> , 2005, 10, 967-968.	1.0	13
49	Effects of HIV-1 Entry Inhibitors in Combination. <i>Current Pharmaceutical Design</i> , 2004, 10, 1861-1865.	1.9	11
50	Favorable Interactions between Enfuvirtide and 1- β -d-2,6-Diaminopurine Dioxolane <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3644-3646.	3.2	7